Results from Phase I

ASCO 2023: Promising Results from Phase I Study of Sleeping Beauty TCR-T Cells Targeting Shared KRAS and TP53 Mutations in Solid Tumors

ASCO 2023: Promising Results from Sleeping Beauty TCR-T Cells

SG Tylor

ABSTRACT NUMBER – 2547 Alaunos’ Clinical TCR Library focuses on targeting the most common mutations found in KRAS, TP53, and ...